RETA Insider Trading Activity and SEC Form 4 Filings
RETA insider trading summary
No open-market insider purchases or sales of Reata Pharmaceuticals Inc (RETA) have been reported on SEC Form 4 in the past 12 months.
Latest RETA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 14, 2023 | Andrea Loewen | SVP, Global Regulatory Affairs | Sell | $546K (3,175 @ $172.03) |
| Sep 5, 2023 | Bhaskar Anand | SVP, Chief Accounting Officer | Sell | $69K (406 @ $169.20) |
| Aug 16, 2023 | Bhaskar Anand | SVP, Chief Accounting Officer | Sell | $35K (210 @ $168.42) |
| Aug 16, 2023 | Dawn Carter Bir | Chief Commercial Officer | Sell | $67K (398 @ $168.33) |
| Aug 16, 2023 | Manmeet Singh Soni | COO, CFO and President | Sell | $296K (1,755 @ $168.41) |
| Aug 16, 2023 | Michael D Wortley | Chief Legal Officer | Sell | $67K (398 @ $168.76) |
| Aug 16, 2023 | Colin John Meyer | Chief Innovation Officer | Sell | $101K (596 @ $168.74) |
| Aug 15, 2023 | Michael D Wortley | Chief Legal Officer | Sell | $136K (807 @ $169.04) |
| Aug 15, 2023 | Colin John Meyer | Chief Innovation Officer | Sell | $362K (2,144 @ $169.07) |
| Aug 15, 2023 | Bhaskar Anand | SVP, Chief Accounting Officer | Sell | $33K (193 @ $169.06) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.